- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941713
Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)
Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children
Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.
This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.
Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.
A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Francoise SCHMITT, MD
- Phone Number: +33 2 41 35 42 90
- Email: FrSchmitt@chu-angers.fr
Study Contact Backup
- Name: Josue Rakotonjanahary
- Phone Number: +33 2 41 35 57 40
- Email: JoRakotonjanahary@chu-angers.fr
Study Locations
-
-
-
Amiens, France, 80054
- CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
-
Contact:
- Philippe BUISSON, MD
- Phone Number: +33 3 22 08 75 60
- Email: buisson.philippe@chu-amiens.fr
-
Principal Investigator:
- Philippe BUISSON, MD
-
Angers, France, 49933
- CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
-
Contact:
- Francoise SCHMITT, MD
- Phone Number: 2 41 35 42 90
- Email: FrSchmitt@chu-angers.fr
-
Contact:
-
Principal Investigator:
- francoise SCHMITT, MD
-
Clermont-Ferrand, France, 63003
- CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
-
Contact:
- Carole Egron, MD
- Phone Number: +33 4 73 75 00 24
- Email: cegron@chu-clermontferrand.fr
-
Principal Investigator:
- Carole EGRON, MD
-
Dijon, France, 21000
- CHU Dijon, Service de chirurgie pédiatrique
-
Contact:
- Michel FRANCOIS, MD
- Phone Number: +33 3 80 28 14 35
- Email: michel.françois@chu-dijon.fr
-
Principal Investigator:
- Michel FRANCOIS, MD
-
Grenoble, France, 38700
- CHU Grenoble, Service de chirurgie pédiatrique
-
Contact:
- Pierre-Yves RABATTU, MD
- Phone Number: +33 4 76 76 59 00
- Email: pyrabattu@chu-grenoble.fr
-
Principal Investigator:
- Pierre-Yves RABATTU, MD
-
Le Kremlin-Bicêtre, France, 94275
- Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
-
Contact:
- Khadidja KHADIR, MD
- Phone Number: +33 1 45 21 21 21
- Email: khadidja.khadir@aphp.fr
-
Principal Investigator:
- Khadidja KHADIR, MD
-
Lyon, France, 69677
- Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
-
Contact:
- Nicolas CARON, MD
- Phone Number: +33 4 72 35 70 50
- Email: nicolas.caron@chu-lyon.fr
-
Principal Investigator:
- Nicolas CARON, MD
-
Nantes, France, 44093
- CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
-
Contact:
- Audrey GUINOT, MD
- Phone Number: +33 2 40 08 35 85
- Email: audrey.guinot@chu-nantes.fr
-
Principal Investigator:
- Audrey GUINOT, MD
-
Paris, France, 75015
- Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
-
Contact:
- Rola ABOU TAAM, MD
- Phone Number: +33 1 44 38 15 65
- Email: rola.aboutaam@aphp.fr
-
Principal Investigator:
- Rola ABOU TAAM, MD
-
Strasbourg, France, 67098
- CHU Strasbourg, Service de chirurgie pédiatrique
-
Contact:
- Isabelle TALON, MD
- Phone Number: +33 3 88 12 73 17
- Email: isabelle.talon@chru-strasbourg.fr
-
Toulouse, France, 31059
- CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
-
Contact:
- Aurélie LE MANDAT, MD
- Phone Number: +33 5 34 55 85 44
- Email: lemandat.a@chu-toulouse.fr
-
Principal Investigator:
- Aurelie LE MANDAT, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).
Description
For thoracoscopy group:
Inclusion Criteria:
- Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Conversion from thoracoscopy to thoracotomy during the procedure
- Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
- For Thoracotomy group*:
Inclusion Criteria :
--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
- Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification
For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.
*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).
**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
thoracoscopy group
minimally invasive surgical approach |
|
thoracotomy arm
conventionnal surgical approach |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Time Frame: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022. |
Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
to evaluate the importance of restrictive syndrome
Time Frame: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]). |
importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
|
Looking for other respiratory parameters
Time Frame: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present |
the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
|
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Time Frame: until spirometry is completed, within a maximum period of 2 years
|
The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10). |
until spirometry is completed, within a maximum period of 2 years
|
|
rate of postoperative complications and any necessary reoperations
Time Frame: up to 2 years after the multidisciplinary consultation
|
The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries. |
up to 2 years after the multidisciplinary consultation
|
|
Respiratory-related quality of life during childhood
Time Frame: up to 2 years after the multidisciplinary consultation
|
It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10). |
up to 2 years after the multidisciplinary consultation
|
|
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Time Frame: through study completion, within a maximum of 24 months
|
The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis). |
through study completion, within a maximum of 24 months
|
|
to assess the mortality rate
Time Frame: through study completion, an average 7 years
|
The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry). |
through study completion, an average 7 years
|
|
Looking for lung volumes variations
Time Frame: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Lung volume variations will be measured by dynamic respiratory MRI data |
the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 49RC25_0432
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.